Larsen et al. (2023) conducted a nationwide population-based cohort study of 44,053 IBD patients (379,862 person-years of follow-up) and found no increase in arrhythmia risk among anti-TNF users compared with unexposed controls (HR 0.95; 95% CI: 0.80-1.13, p = 0.79) [14]. The gene discussed is TNF; the disease is inflammatory bowel disease.